MedTrace Logo

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

NCT00254995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62626

Last updated 2016-04-19

Study results available
· View outcomes & findings →

Summary

To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

Conditions

Interventions

BIOLOGICAL

None administered in this study

N/A in this study

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur Inc.

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00254995 on ClinicalTrials.gov